Last reviewed · How we verify
Therapy to Maintain Remission in Dilated Cardiomyopathy (TRED-HF2)
One third of patients diagnosed with heart failure demonstrate left ventricular reverse remodelling and recovery of cardiac function following a period of medical therapy. The TRED-HF trial investigated the impact of therapy withdrawal in this cohort and found that 40% of patients relapsed within 6 months of stopping treatment. In this follow-on study, the investigators will investigate the safety of therapy withdrawal of sodium cotransporter 2 inhibitors (SGLT2i) and mineralocorticord receptor anatagonists (MRAs) in patients with a previous diagnosis of heart failure and recovered cardiac function, in a randomised controlled trial to assess whether this maintains remission in this population.
Details
| Lead sponsor | Imperial College London |
|---|---|
| Phase | NA |
| Status | RECRUITING |
| Enrolment | 50 |
| Start date | Sat Dec 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Sep 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Heart Failure
- Cardiomyopathy, Dilated
- Cardiomyopathies
- Heart Diseases
Interventions
- Other
Countries
United Kingdom